Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
Clinical trial NCT02397096 · COMPLETED
Trial details
- NCT number
- NCT02397096
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-09
- Primary completion
- 2018-02-22
- Enrollment
- 673
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.